Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) drug registration application for the Fovinaciclib citrate capsules by unit Jinzhou Avanc Pharmaceutical, has been accepted by China's National Medical Products Administration, a Thursday bourse filing said.
The indication under the application is locally advanced or metastatic breast cancer, where the drug should be used in combination with an aromatase inhibitor as initial endocrine therapy for premenopausal, postmenopausal, and perimenopausal female patients with breast cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.